JP2024521667A5 - - Google Patents

Info

Publication number
JP2024521667A5
JP2024521667A5 JP2023571224A JP2023571224A JP2024521667A5 JP 2024521667 A5 JP2024521667 A5 JP 2024521667A5 JP 2023571224 A JP2023571224 A JP 2023571224A JP 2023571224 A JP2023571224 A JP 2023571224A JP 2024521667 A5 JP2024521667 A5 JP 2024521667A5
Authority
JP
Japan
Prior art keywords
combination pharmaceutical
cancer
antibody
antigen
use according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023571224A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024521667A (ja
Filing date
Publication date
Priority claimed from GBGB2107518.9A external-priority patent/GB202107518D0/en
Priority claimed from GBGB2108387.8A external-priority patent/GB202108387D0/en
Priority claimed from GBGB2109271.3A external-priority patent/GB202109271D0/en
Application filed filed Critical
Priority claimed from PCT/GB2022/051256 external-priority patent/WO2022248835A1/en
Publication of JP2024521667A publication Critical patent/JP2024521667A/ja
Publication of JP2024521667A5 publication Critical patent/JP2024521667A5/ja
Pending legal-status Critical Current

Links

JP2023571224A 2021-05-26 2022-05-19 抗-cd205抗体及び免疫チェックポイント・インヒビターを含む組み合わせ医薬 Pending JP2024521667A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
GB2107518.9 2021-05-26
GBGB2107518.9A GB202107518D0 (en) 2021-05-26 2021-05-26 Pharmaceutical composition
GBGB2108387.8A GB202108387D0 (en) 2021-06-11 2021-06-11 Pharmaceutical composition
GB2108387.8 2021-06-11
GB2109271.3 2021-06-28
GBGB2109271.3A GB202109271D0 (en) 2021-06-28 2021-06-28 Pharmaceutical composition
PCT/GB2022/051256 WO2022248835A1 (en) 2021-05-26 2022-05-19 Pharmaceutical combination comprising an anti-cd205 antibody and an immune checkpoint inhibitor

Publications (2)

Publication Number Publication Date
JP2024521667A JP2024521667A (ja) 2024-06-04
JP2024521667A5 true JP2024521667A5 (cg-RX-API-DMAC7.html) 2025-05-07

Family

ID=81851367

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023571224A Pending JP2024521667A (ja) 2021-05-26 2022-05-19 抗-cd205抗体及び免疫チェックポイント・インヒビターを含む組み合わせ医薬

Country Status (10)

Country Link
US (1) US20240254238A1 (cg-RX-API-DMAC7.html)
EP (1) EP4346882A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024521667A (cg-RX-API-DMAC7.html)
KR (1) KR20240013732A (cg-RX-API-DMAC7.html)
AU (1) AU2022282609A1 (cg-RX-API-DMAC7.html)
BR (1) BR112023023831A2 (cg-RX-API-DMAC7.html)
CA (1) CA3219316A1 (cg-RX-API-DMAC7.html)
IL (1) IL308545A (cg-RX-API-DMAC7.html)
MX (1) MX2023013574A (cg-RX-API-DMAC7.html)
WO (1) WO2022248835A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN121843714A (zh) 2023-08-11 2026-04-10 派拉冈医疗公司 Tl1a结合抗体及使用方法

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4475196A (en) 1981-03-06 1984-10-02 Zor Clair G Instrument for locating faults in aircraft passenger reading light and attendant call control system
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4486194A (en) 1983-06-08 1984-12-04 James Ferrara Therapeutic device for administering medicaments through the skin
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
US5374548A (en) 1986-05-02 1994-12-20 Genentech, Inc. Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor
MX9203291A (es) 1985-06-26 1992-08-01 Liposome Co Inc Metodo para acoplamiento de liposomas.
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US5108921A (en) 1989-04-03 1992-04-28 Purdue Research Foundation Method for enhanced transmembrane transport of exogenous molecules
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
ES2156149T3 (es) 1992-12-04 2001-06-16 Medical Res Council Proteinas de union multivalente y multiespecificas, su fabricacion y su uso.
US6214345B1 (en) 1993-05-14 2001-04-10 Bristol-Myers Squibb Co. Lysosomal enzyme-cleavable antitumor drug conjugates
EP1243276A1 (en) 2001-03-23 2002-09-25 Franciscus Marinus Hendrikus De Groot Elongated and multiple spacers containing activatible prodrugs
CA2453822C (en) 2001-08-03 2011-02-22 Tyco Healthcare Group Lp Tissue marking apparatus and method
DK1545613T3 (da) 2002-07-31 2011-11-14 Seattle Genetics Inc Auristatinkonjugater og deres anvendelse til behandling af cancer, en autoimmun sygdom eller en infektiøs sygdom
EP1391213A1 (en) 2002-08-21 2004-02-25 Boehringer Ingelheim International GmbH Compositions and methods for treating cancer using maytansinoid CD44 antibody immunoconjugates and chemotherapeutic agents
WO2004026293A2 (en) 2002-09-20 2004-04-01 Wyeth Holdings Corporation Hemiasterlin derivatives for treating resistant tumors
WO2004043493A1 (en) 2002-11-14 2004-05-27 Syntarga B.V. Prodrugs built as multiple self-elimination-release spacers
EP2478912B1 (en) 2003-11-06 2016-08-31 Seattle Genetics, Inc. Auristatin conjugates with anti-HER2 or anti-CD22 antibodies and their use in therapy
US7691962B2 (en) 2004-05-19 2010-04-06 Medarex, Inc. Chemical linkers and conjugates thereof
JP4806680B2 (ja) 2004-05-19 2011-11-02 メダレックス インコーポレイテッド 自己犠牲リンカー及び薬剤複合体
DK1791565T3 (en) 2004-09-23 2016-08-01 Genentech Inc Cysteingensplejsede antibodies and conjugates
US7714016B2 (en) 2005-04-08 2010-05-11 Medarex, Inc. Cytotoxic compounds and conjugates with cleavable substrates
US8158590B2 (en) 2005-08-05 2012-04-17 Syntarga B.V. Triazole-containing releasable linkers, conjugates thereof, and methods of preparation
WO2007059404A2 (en) 2005-11-10 2007-05-24 Medarex, Inc. Duocarmycin derivatives as novel cytotoxic compounds and conjugates
US8940784B2 (en) 2006-02-02 2015-01-27 Syntarga B.V. Water-soluble CC-1065 analogs and their conjugates
WO2008104803A2 (en) 2007-02-26 2008-09-04 Oxford Genome Sciences (Uk) Limited Proteins
CA2695297C (en) 2007-08-01 2017-03-21 Syntarga B.V. Substituted cc-1065 analogs and their conjugates
CN101888856B (zh) 2007-11-07 2014-08-27 塞尔德克斯医疗公司 结合人树突和上皮细胞205(dec-205)的抗体
ES2647317T3 (es) 2008-11-03 2017-12-20 Syntarga B.V. Análogos de CC-1065 y sus conjugados
CN105745224B (zh) 2013-10-11 2019-11-05 牛津生物疗法有限公司 用于治疗癌症的针对ly75的偶联抗体
GB201703876D0 (en) * 2017-03-10 2017-04-26 Berlin-Chemie Ag Pharmaceutical combinations
SG11202000073XA (en) * 2017-07-24 2020-02-27 Regeneron Pharma Anti-cd8 antibodies and uses thereof
MX2020004381A (es) * 2017-10-27 2020-08-20 Pfizer Anticuerpos y conjugados de anticuerpo-farmaco especificos para cd123 y usos de los mismos.
GB201809746D0 (en) * 2018-06-14 2018-08-01 Berlin Chemie Ag Pharmaceutical combinations

Similar Documents

Publication Publication Date Title
Hutchings et al. Glofitamab step-up dosing induces high response rates in patients with hard-to-treat refractory or relapsed non-Hodgkin lymphoma
RU2423382C1 (ru) Композиции и способы диагностики и лечения опухоли
US10792370B2 (en) Antibody-drug conjugate
RU2007135167A (ru) Комбинированная терапия с использованием анти-ctla4-антитела и индолинона для лечения рака
JP2023517243A5 (cg-RX-API-DMAC7.html)
JP2023507190A5 (cg-RX-API-DMAC7.html)
WO2023035611A1 (en) Pharmaceutical composition and use thereof
JP2020510039A5 (cg-RX-API-DMAC7.html)
JP2021511372A5 (cg-RX-API-DMAC7.html)
Lugtenburg et al. First-in-Human, Phase 1/2 Trial to Assess the Safety and Clinical Activity of Subcutaneous GEN3013 (DuoBodyŪ-CD3ŨCD20) in B-Cell Non-Hodgkin Lymphomas
JP2023519807A5 (cg-RX-API-DMAC7.html)
JP2024521667A5 (cg-RX-API-DMAC7.html)
WO2020233602A1 (zh) 用于联合治疗小细胞肺癌的喹啉衍生物
JP2024506684A5 (cg-RX-API-DMAC7.html)
ES2969732T3 (es) Régimen de tratamiento del cáncer una vez al día con un inhibidor de PRMT5
JP2022502508A5 (cg-RX-API-DMAC7.html)
Brown et al. Antiseizure medication use in gastric bypass patients and other post-surgical malabsorptive states
CN111973747A (zh) 用于联合治疗卵巢癌的喹啉衍生物
WO2012156975A9 (en) COMBINATIONS OF ANTI ErbB ANTIBODIES FOR THE TREATMENT OF CANCER
JP2025509567A5 (cg-RX-API-DMAC7.html)
JP2021518348A5 (cg-RX-API-DMAC7.html)
JP2022513029A5 (cg-RX-API-DMAC7.html)
JP2024536383A5 (cg-RX-API-DMAC7.html)
CN105142664A (zh) 投予抗gcc抗体-药物结合物和dna破坏剂来治疗癌症
JP2023500480A5 (cg-RX-API-DMAC7.html)